Acumen Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	47.16	67.12	130.1	122.16	43.78	6.55
Short-Term Investments	205.58	176.64	47.5	72.08	0	0
Cash & Cash Equivalents	252.75	243.76	177.61	194.24	43.78	6.55
Cash Growth	80.01%	37.25%	-8.56%	343.70%	568.15%	-
Receivables	0	0	0	0	0.11	0.03
Other Current Assets	3.09	2.86	2.72	4.42	0.54	0.6
Total Current Assets	255.83	246.62	180.33	198.66	44.43	7.18
Property, Plant & Equipment	0.47	0.5	0.27	0.04	0	0
Long-Term Investments	44.11	62.55	15.84	31.62	0	0
Other Long-Term Assets	0.56	0.45	0.15	0.01	0	0.14
Total Long-Term Assets	45.14	63.51	16.26	31.67	0	0.14
Total Assets	300.97	310.13	196.59	230.33	44.43	7.32
Accounts Payable	3.08	1.38	1.64	1.09	0.53	0.22
Current Debt	0.12	0.87	0.11	0	0	0
Other Current Liabilities	5.27	10.73	6.07	4.06	5.84	1.12
Total Current Liabilities	8.47	12.97	7.81	5.15	6.37	1.34
Long-Term Debt	30.46	30.18	0	0	0	0
Total Long-Term Liabilities	30.46	30.18	0	0	0	0
Total Liabilities	38.93	43.15	7.81	5.15	6.37	1.34
Total Debt	30.58	31.05	0.11	0	0	0
Debt Growth	45544.78%	29468.57%	-	-	-	-
Retained Earnings	-237.67	-222.8	-170.43	-127.57	-26.97	-19.64
Comprehensive Income	-0.14	0.31	-0.75	-0.23	0	0
Shareholders' Equity	262.03	266.97	188.78	225.18	-18.59	-11.42
Net Cash / Debt	222.16	212.71	177.5	194.24	43.78	6.55
Net Cash / Debt Growth	58.30%	19.84%	-8.62%	343.70%	568.15%	-
Net Cash Per Share	3.71	4.38	4.37	9.68	104.45	15.21
Working Capital	247.36	233.64	172.52	193.51	38.06	5.84
Book Value Per Share	4.38	5.49	4.65	11.23	-44.36	-26.51

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).